{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:41:04Z","timestamp":1789389664475,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.bcmd.2017.08.017","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T13:23:14Z","timestamp":1507814594000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent"],"prefix":"10.1016","volume":"69","author":[{"given":"Paolo","family":"Rigano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"De Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sainati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric B.","family":"Piel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Fidone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Masera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Palazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gianesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Forni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9757","key":"10.1016\/j.bcmd.2017.08.017_bb0005","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bcmd.2017.08.017_bb0010","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bcmd.2017.08.017_bb0015","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1172\/JCI111464","article-title":"Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia","volume":"74","author":"Platt","year":"1984","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bcmd.2017.08.017_bb0020","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V79.10.2555.2555","article-title":"Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia","volume":"79","author":"Charache","year":"1992","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.bcmd.2017.08.017_bb0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2008.05.001","article-title":"Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea","volume":"15","author":"Cartron","year":"2008","journal-title":"Transfusion clinique et biologique: journal de la Societe francaise de transfusion sanguine."},{"issue":"11","key":"10.1016\/j.bcmd.2017.08.017_bb0030","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3181\/0811-RM-339","article-title":"Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation","volume":"234","author":"Lou","year":"2009","journal-title":"Exp. Biol. Med. (Maywood)."},{"issue":"20","key":"10.1016\/j.bcmd.2017.08.017_bb0035","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcmd.2017.08.017_bb0040","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1542\/peds.2008-0441","article-title":"Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children","volume":"122","author":"Strouse","year":"2008","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.bcmd.2017.08.017_bb0045","doi-asserted-by":"crossref","first-page":"939","DOI":"10.7326\/0003-4819-148-12-200806170-00221","article-title":"Systematic review: hydroxyurea for the treatment of adults with sickle cell disease","volume":"148","author":"Lanzkron","year":"2008","journal-title":"Ann. Intern. Med."},{"issue":"9778","key":"10.1016\/j.bcmd.2017.08.017_bb0050","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.bcmd.2017.08.017_bb0055","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.bcmd.2017.08.017_bb0060","first-page":"1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial. Pediatric Hydroxyurea Group","volume":"94","author":"Kinney","year":"1999","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcmd.2017.08.017_bb0065","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"McGann","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.bcmd.2017.08.017_bb0070","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bjh.12323","article-title":"The effect of hydroxcarbamide therapy on survival of children with sickle cell disease","volume":"161","author":"Lobo","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.bcmd.2017.08.017_bb0075","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","article-title":"The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)","volume":"115","author":"Voskaridou","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcmd.2017.08.017_bb0080","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.bcmd.2017.08.017_bb0085","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/pbc.25608","article-title":"Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment","volume":"62","author":"Le","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"12","key":"10.1016\/j.bcmd.2017.08.017_bb0090","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7326\/0003-4819-148-12-200806170-00220","article-title":"National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease","volume":"148","author":"Brawley","year":"2008","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.bcmd.2017.08.017_bb0095","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2214-109X(13)70150-5","article-title":"Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000","volume":"2","author":"Piel","year":"2014","journal-title":"Lancet Glob. Health"},{"issue":"1","key":"10.1016\/j.bcmd.2017.08.017_bb0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21550","article-title":"Definitions of the phenotypic manifestations of sickle cell disease","volume":"85","author":"Ballas","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.bcmd.2017.08.017_bb0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.113.002124","article-title":"Prevalence and risk factors for pulmonary arterial hypertension in a large group of \u03b2-thalassemia patients using right heart catheterization: a Webthal study","volume":"129","author":"Derchi","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.bcmd.2017.08.017_bb0110","first-page":"S1","article-title":"K\/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am. J. Kidney Dis."},{"issue":"13","key":"10.1016\/j.bcmd.2017.08.017_bb0115","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2017.08.017_bb0120","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ajh.20703","article-title":"Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea","volume":"81","author":"Lanzkron","year":"2006","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2017.08.017_bb0125","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7326\/0003-4819-148-12-200806170-00220","article-title":"National institutes of health consensus development conference statement: hydroxyurea treatment for sickle cell disease","volume":"148","author":"Brawley","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcmd.2017.08.017_bb0130","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","author":"Ware","year":"2015","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.bcmd.2017.08.017_bb0135","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","article-title":"Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)","volume":"119","author":"Ware","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bcmd.2017.08.017_bb0140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1401731","article-title":"Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia","volume":"371","author":"DeBaun","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcmd.2017.08.017_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1081\/HEM-100103065","article-title":"Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S\/beta-thalassemia","volume":"25","author":"Rigano","year":"2001","journal-title":"Hemoglobin"},{"issue":"7","key":"10.1016\/j.bcmd.2017.08.017_bb0150","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2015-09-618579","article-title":"Central nervous system complications and management in sickle cell disease","volume":"127","author":"DeBaun","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcmd.2017.08.017_bb0155","doi-asserted-by":"crossref","first-page":"E261","DOI":"10.1002\/ajh.23531","article-title":"Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians","volume":"88","author":"Rigano","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.bcmd.2017.08.017_bb0160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.10427","article-title":"Malignancy in patients with sickle cell disease","volume":"74","author":"Schultz","year":"2003","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.bcmd.2017.08.017_bb0165","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/asheducation-2014.1.432","article-title":"Does hydroxyurea prevent pulmonary complications of sickle cell disease?","volume":"2014","author":"Buckner","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"issue":"1","key":"10.1016\/j.bcmd.2017.08.017_bb0170","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1183\/09031936.00134410","article-title":"Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease","volume":"39","author":"Fonseca","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.bcmd.2017.08.017_bb0175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1005565","article-title":"A hemodynamic study of pulmonary hypertension in sickle cell disease","volume":"365","author":"Parent","year":"2011","journal-title":"N. Engl. J. Med."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979617303224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979617303224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:10Z","timestamp":1761050050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979617303224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":35,"alternative-id":["S1079979617303224"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.08.017","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}